Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

p>
    Recent Highlights
    Pirfenidone:

    -- On October 16, 2008 Shionogi & Co., Ltd of Japan, which has rights to
       pirfenidone in Japan, reported approval of its j-NDA to market
       pirfenidone as Pirespa(R) in IPF.
    -- On February 3, 2009, InterMune reported results from its Phase 3
       CAPACITY program for pirfenidone in IPF, which consisted of two,
       multinational, randomized, double-blind, placebo-controlled clinical
       trials named CAPACITY 1 and CAPACITY 2.
        - The primary endpoint of change in percent predicted Forced Vital
          Capacity (FVC) at Week 72 was met with statistical significance in
          CAPACITY 2 (p=0.001), as were the secondary endpoints of categorical
          change in FVC (p=0.001) and Progression-Free Survival  (p=0.023).
        - The primary endpoint was not met in CAPACITY 1 (p=0.501), but
          supportive evidence of a pirfenidone treatment effect was observed
          on a number of measures and at various time points.  In CAPACITY 1,
          there was evidence of a pirfenidone treatment effect on the
          pre-specified secondary endpoint of Six-Minute Walk Test distance
          (p = 0.001) when compared to placebo.
        - Pirfenidone was safe and generally well tolerated in both CAPACITY
          studies.  There was no difference between pirfenidone and placebo in
          the percentage of patients that experienced a serious adverse event
          (SAE) and the pattern of adverse events (AEs) was, in general,
          comparable to that observed in previous clinical studies of
          pirfenidone.
        - InterMune is preparing an NDA for submission to the FDA, to be
          followed by an MAA submission to the European Medicines Agency
          (EMEA).
    -- InterMune reported that 603 patients from CAPACITY have been enrolled
       in RECAP, the on-going open-label roll-over study from CAPACITY to
       evaluat
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Wis. - At least six Wisconsin biotech companies ... an event that may be another signal of the ... , ,The Wisconsin companies will travel to Minneapolis for ... by the Biotechnology Industry Organization . Companies will ...
... Madison, Wis. - The Center for Technology Transfer ... Spinworks LLC, a company that has developed a series ... to reduce usage of natural gas in their furnaces. , ... and will help Spinworks expand its business and product offerings, ...
... Active Air Networks Wisconsin said Monday it ... to consumers and business users throughout Wisconsin communities. ... multiple villages and towns throughout Washington County. Its citywide ... 802.11 a/b/g Wi-Fi standards. The service is mobile, yet ...
Cached Biology Technology:Six Wisconsin firms to present at BIO Mid-America VentureForum 2Six Wisconsin firms to present at BIO Mid-America VentureForum 3Tech center supports energy-saving device for heat-treating plants 2
(Date:4/22/2014)... from NeuroPhage Pharmaceuticals, Inc. have engineered a series ... neurodegenerative diseases that are characterized by misfolded proteins, ... molecules are based on what the Company calls ... recognizes a characteristic common to many toxic, misfolded ... This approach provides NeuroPhage with an array of ...
(Date:4/21/2014)... at The University of Texas at Dallas have ... carbon structures used in the manufacture of many ... Paul Pantano, associate professor of chemistry, and Dr. ... recently received a $459,000, three-year grant from the ... the National Institutes of Health, to track how ...
(Date:4/21/2014)... colleagues from Pittsburgh University, find how lipid mediators ... Nature Chemistry. Lipid mediators are molecules playing an ... to some of them has earned a Nobel ... "cellular power plants", the organelles where oxidation of ... (ATP), a molecule universally used for storage and ...
Breaking Biology News(10 mins):NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 2NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 3Grant to fund research on possible cell contaminants 2Grant to fund research on possible cell contaminants 3The anti-inflammatory factory 2The anti-inflammatory factory 3
... Western Europe,s largest lakes, Lake Geneva, in large enough quantities ... that these small bits of plastic can be harmful to ... waterborne organisms, the full extent of their consequences in lakes ... is being extending under a mandate by the Swiss Federal ...
... paper published in the Journal of Animal Science ... when including distillers dried grains with solubles (DDGS). Some ... the fat-softening effects of DDGS. Firmer fat means longer-lasting ... found that including saturated fats in DDGS diets makes ...
... to threaten common ash trees across Europe, new research in ... impact of forest diseases to discover if diseases played a ... large-scale pathogen outbreaks were much more infrequent in the past, ... locations, such as the international seed trade, is a major ...
Cached Biology News:Microplastic pollution prevalent in lakes too 2Microplastic pollution prevalent in lakes too 3Saturated fats do not yield better bacon 2
Mycoplasma tested...
Human PDGF, CF...
... Lacks the mycobacteria found ... side-effects. For this reason, Incomplete, ... Freund's Adjuvants may be used to produce water-in-oil ... emulsions stimulate high and long-lasting antibody responses which ...
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: